Skip to main content

Advertisement

Table 1 Hospitalization rates

From: Immunoprophylaxis of respiratory syncytial virus: global experience

  Children ≤ 2 years old with BPD/CLD (n = 3675) Infants at gestational age 29–32 weeks without CLD (n = 4854) Infants at gestational age 32–35 weeks without CLD (n = 2829)
Reference (country) Untreated Palivizumab Untreated Palivizumab Untreated Palivizumab
[23] (USA) 36.7% (30) - - - - -
[24] (USA) 17.4% (149) - - - - -
[52] (USA) 25.2% (131) - 7.6% (662) - - -
[53] (UK) 19.1% (235) - - - - -
[32] (USA/Can/UK) 12.8% (266) 7.9% (496) 8.5% (142) 1.6% (313) 9.8% (123) 2.0% (250)
[35] (USA; outcomes 1998–1999) - 4.0% (402) - 2.0% (506) - 1.5% (548)
[36] (USA; outcomes 1999–2000) - 3.9% (795) - 2.3% (690) - 1.3% (972)
[39] (Canada) - 6.0% (95) - 1.3% (199) - -
[40] (The Netherlands) - 3.4% (88) - 0.8% (124) - -
Unpublished data (France) - 7.6% (506) - - - -
[37] (USA; registry 2000–2001) - 5.8% (482) - 2.3% (650) - 1.6% (936)
[54] (Spain) - - 10.1% (456) - - -
[55] (Spain) - - 12.9% (827) - - -
[41] (international study) - - - 2.1% (285) - -
Weighted mean rate 18.4% (811) 5.6% (2864) 10.3% (2087) 2.0% (2767) 9.8% (123) 1.5% (2706)
  1. Values are expressed as % (n). Hospitalization rates due to respiratory syncytial virus (RSV) in children ≤ 2 years old with bronchopulmonary dysplasia (BPD)/chronic lung disease (CLD), infants at gestational age 29–32 weeks without CLD, and infants at gestational age 32–35 weeks without CLD (combined analysis). -, not studied. Adapted from Simoes [44].